RxDoctor Payments DataLook up a doctor →

Ravi Chauhan, MD

Urology · Germantown, TNNPI 1588621254

Payments from drug & device makers

$181,828in general payments, 2019–2025

Across 486 payments — averaging $374.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ferring Pharmaceuticals Inc.$124K
  • Merck$12K
  • Intuitive Surgical$10K
  • Johnson & Johnson$8K
  • Urogen Pharma, Inc.$5K
  • Astellas Pharma US Inc$3K
  • plus $20K from 42 others

What the payments were for

  • Consulting fees$22,04012%
  • Speaking & faculty fees$112,09662%
  • Travel & lodging$29,15016%
  • Food & beverage$15,5419%
  • Education$3,0002%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$181,828 in reported general payments places this provider in the 90th percentile of 276 urology providers in Tennessee.

See all urology providers in Tennessee

Medicare billing

Part B allowed, 2024
$1,223,990
Medicare patients
1,571
Services billed
80,413

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix31$79,959
MyrbetriqMirabegron82$71,355
GemtesaVibegron40$35,755
Tamsulosin Hcl737$12,652
NitrofurantoinNitrofurantoin Macrocrystal83$4,372
Oxybutynin Chloride ErOxybutynin Chloride122$3,952
Testosterone11$3,420
Solifenacin Succinate53$3,409
Finasteride252$3,131
Testosterone Cypionate76$2,410
Alfuzosin Hcl ErAlfuzosin Hcl54$1,316
Potassium Citrate ErPotassium Citrate14$1,256
Oxybutynin Chloride12$826
Ciprofloxacin Hcl231$788
Dutasteride20$540

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$641$115,71471 claims
Astellas Pharma US IncMyrbetriq$3,171$71,35582 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 276 urology providers in Tennessee.

Other urology in Germantown

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →